<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440152</url>
  </required_header>
  <id_info>
    <org_study_id>2014-15</org_study_id>
    <nct_id>NCT02440152</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention</brief_title>
  <official_title>The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Suzhou Sceneray Medical Co. , Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institution of Neuroscience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The nucleus accumbens (NAcc) has a significant role in the process of opiate addiction and
      the initiation of relapse after detoxification. There is evidence that deep brain stimulation
      (DBS) of the NAcc exerts a positive effect on individuals with severe heroin addiction via
      inhibitory action .

      The investigators hypothesise that bilateral stimulation of the NAcc will significantly
      reduce withdrawal symptoms and thus enable the patients to substantially decrease their
      Levomethadone usage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weekly urine tests</measure>
    <time_frame>Baseline (preoperative), 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 10-point visual analog scale (VAS) craving score for opioid drugs</measure>
    <time_frame>Baseline (preoperative), 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Anxiety Scale</measure>
    <time_frame>Baseline (preoperative), 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Depression Scale-17</measure>
    <time_frame>Baseline (preoperative), 3 months, 6 months, 9 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 assessment</measure>
    <time_frame>Baseline (preoperative), 6 months, 12 month, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological measures（Scores of Iowa gambling task and Model task）</measure>
    <time_frame>Baseline (preoperative), Intraoperative,6 months,12month,24month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Opiate Addiction</condition>
  <arm_group>
    <arm_group_label>Deep brain stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suzhou Sceneray® DBS System</intervention_name>
    <description>We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).</description>
    <arm_group_label>Deep brain stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proficiency in Mandarin language

          -  Long lasting heroin addiction (determined by diagnostic-criteria in Diagnostic and
             Statistical Manual of Mental Disorders, Fifth Edition)

          -  Duration longer than 6 months

          -  A lack of response to long-term treatment

          -  Capacity to provide informed consent (understanding of the study purpose and methods)

          -  Substitution methadone treatment at a constant dose within three months prior to
             inclusion.

        Exclusion Criteria:

          -  Clinical relevant psychiatric comorbidity (schizophrenic psychoses, bipolar affective
             diseases with psychotic symptoms)(MINI 6.0)

          -  Past stereotactic neurosurgical intervention

          -  Neurological disease (Abnormal PET-CT, MRI, EEG)

          -  Contraindications of MRI-examination, e.g. implanted cardiac pacemaker/ heart
             defibrillator

          -  Contraindications of stereotactic intervention, e.g. increased bleeding-disposition,
             cerebrovascular diseases (e.g. arteriovenous malfunction, aneurysms, systemic vascular
             diseases)

          -  Serious and unstable organic diseases (e.g. unstable coronal heart disease)

          -  HIV positive

          -  Pregnancy and/or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bomin Sun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ChenCheng Zhang, MD</last_name>
    <email>i@cczhang.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristina Zeljic, MSc</last_name>
    <email>zeljickristina@ion.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai RuiJin Hospital Psychitric Department</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyan Jin, MD</last_name>
      <email>hyjin603@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Du, MD</last_name>
      <email>dujiangdou@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Min Zhao, MD,PhD</last_name>
      <email>drzhaomin@sh163.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Luigjes J, van den Brink W, Feenstra M, van den Munckhof P, Schuurman PR, Schippers R, Mazaheri A, De Vries TJ, Denys D. Deep brain stimulation in addiction: a review of potential brain targets. Mol Psychiatry. 2012 Jun;17(6):572-83. doi: 10.1038/mp.2011.114. Epub 2011 Sep 20. Review.</citation>
    <PMID>21931318</PMID>
  </reference>
  <results_reference>
    <citation>Kuhn J, Möller M, Treppmann JF, Bartsch C, Lenartz D, Gruendler TO, Maarouf M, Brosig A, Barnikol UB, Klosterkötter J, Sturm V. Deep brain stimulation of the nucleus accumbens and its usefulness in severe opioid addiction. Mol Psychiatry. 2014 Feb;19(2):145-6. doi: 10.1038/mp.2012.196. Epub 2013 Jan 22.</citation>
    <PMID>23337942</PMID>
  </results_reference>
  <results_reference>
    <citation>Valencia-Alfonso CE, Luigjes J, Smolders R, Cohen MX, Levar N, Mazaheri A, van den Munckhof P, Schuurman PR, van den Brink W, Denys D. Effective deep brain stimulation in heroin addiction: a case report with complementary intracranial electroencephalogram. Biol Psychiatry. 2012 Apr 15;71(8):e35-7. doi: 10.1016/j.biopsych.2011.12.013. Epub 2012 Jan 26.</citation>
    <PMID>22281120</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou H, Xu J, Jiang J. Deep brain stimulation of nucleus accumbens on heroin-seeking behaviors: a case report. Biol Psychiatry. 2011 Jun 1;69(11):e41-2. doi: 10.1016/j.biopsych.2011.02.012. Epub 2011 Apr 13.</citation>
    <PMID>21489407</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Bomin Sun</investigator_full_name>
    <investigator_title>Department of Functional Neurosurgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

